Trial reportRespiration; international review of thoracic diseases2019
The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema.
Trial report in Respiration; international review of thoracic diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Expert Statement: Pneumothorax Associated with One-Way Valve Therapy for Emphysema: 2020 Update.Respiration; international review of thoracic diseasesGuideline
- Sustained Clinical Benefits of Spiration Valve System in Patients with Severe Emphysema: 24-Month Follow-Up of EMPROVE.Annals of the American Thoracic Society · 2024Trial
- Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial.American journal of respiratory and critical care medicine · 2019Trial
- Observational
- Endobronchial Valves for Bronchoscopic Lung Volume Reduction in Severe Emphysema: A Reversible and Non-Surgical Treatment for Patients Who May or May Not Be Candidates for Lung Transplantation.Diagnostics (Basel, Switzerland) · 2026Review
- Bronchoscopic endobronchial valves.Breathe (Sheffield, England) · 2026Review
- Transforming pulmonary care with applications of endobronchial valves beyond emphysema: a narrative review.Annals of translational medicine · 2025Review
- Article
- Bronchoscopic lung volume reduction: model for assisted target lobe selection.BMJ open respiratory research · 2025Article
- Bronchoscopic Lung Volume Reduction: A Narrative Review and Proposal for the Inclusion Criteria.Journal of clinical medicine · 2025Review
- Comparison of Efficacy and Safety of Different Types of One-Way Valves in Endoscopic Lung Volume Reduction in Patients with Severe Lung Emphysema.Respiration; international review of thoracic diseases · 2025Observational
- Limited Benefit of Additional ChartisInternational journal of chronic obstructive pulmonary disease · 2025Article
- Clinical improvements after endoscopic lung volume reduction with valves in patients with advanced emphysema and a 6-min walk test ≤140 m at baseline.ERJ open research · 2025Article
- The effect of bronchoscopic lung volume reduction on the bronchodilator response.Journal of thoracic disease · 2024Article
- Interventional pulmonology for chronic inflammatory airway diseases.Chinese medical journal pulmonary and critical care medicine · 2024Review
- A preclinical animal study to evaluate the operability and safety of domestic one-way endobronchial valves.Frontiers in medicine · 2024Article
- Surgical and bronchoscopic pulmonary function-improving procedures in lung emphysema.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Surgical and Interventional Approaches in COPD.Respiratory care · 2023Review
- Bronchoscopic Management of COPD and Advances in Therapy.Life (Basel, Switzerland) · 2023Review
- Which Endoscopic Procedure to Use and in What Patient? Valves, Coils, Foam, and Heat in COPD and Asthma.Pulmonary therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease (COPD) has become a leading cause of morbidity and mortality in China, with tobacco smoke, air pollution, and occupational biohazards being the major risk factors.
objectivesThe REACH trial is a multicenter, prospective, randomized controlled trial undertaken in China to assess the safety and effectiveness of the Spiration® Valve System (SVS) compared to standard medical care in COPD patients with severe emphysema.
methodsPatients with severe airflow obstruction, hyperinflation, and severe dyspnea with interlobar fissure integrity were evaluated for enrollment. A total of 107 subjects were randomized in a 2: 1 allocation ratio to either the treatment group (SVS valves and medical management) or the control group (medical management alone).
resultsThe 3-month primary endpoint showed statistically significant improvement in forced expiratory volume in 1 s in the treatment group compared to the control group (0.104 ± 0.18 vs. 0.003 ± 0.15 L, p = 0.001), with the difference being durable through 6 months. Statistically significant target lobe volume reduction was achieved at 3 months (mean change 684.4 ± 686.7 mL) and through 6 months (757.0 ± 665.3 mL). Exercise function and quality of life measures improved in the treatment group, but showed a deterioration in the control group. The serious adverse event (SAE) rate was 33% in the treatment group and 24.2% in the control group. The predominance of SAEs were acute exacerbations of COPD in both groups. There was 1 death in the control group and no deaths in the treatment group.
conclusionThe SVS represents a novel approach for the treatment of severe emphysema with a clinically acceptable risk-benefit profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.